Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

Perspectives on Digital Disruption

Posted by Matt Breese on Nov 28, 2017

Digital tools are transforming pharma's approach to market access. As the digital landscape evolves, pharmacy and therapeutics (P&T) committees are embracing digital sources to make informed decisions about formulary placements.

Today, P&T members regularly rely on digital resources throughout the formulary decision-making process. 

Read More

Topics: Market Access, Payer

MMIT Reality Check on G-CSF (Nov 2017)

Posted by Matt Breese on Nov 19, 2017

According to our recent payer coverage analysis for G-CSF treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Trends That Matter for Chronic Heart Failure

Posted by Matt Breese on Nov 16, 2017

Heart failure is one of the most common causes of patient hospitalization in the U.S. However, the mechanisms behind this are not fully understood in the medical field. 

For providers treating patients with chronic heart failure, new technology could drastically improve the success of treatment. UCLA researchers have created a virtual model that can test pharmaceuticals based on patient scenarios to prevent adverse events.

Read More

Topics: Specialty, Market Access

MMIT Reality Check on Heart Failure (Nov 2017)

Posted by Matt Breese on Nov 7, 2017

According to our recent payer coverage analysis for chronic heart failure treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

MMIT Reality Check on Dermatology: Acne (Oct 2017)

Posted by Matt Breese on Oct 30, 2017

According to our recent payer coverage analysis for dermatology-acne, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Payer, Branding & Marketing

Trends That Matter for Narcotic Pain Treatment

Posted by Matt Breese on Oct 26, 2017

The FDA's Opioids Action Plan was recently developed with the goals of reducing incidents of opioid abuse in the United States, while still ensuring patients with chronic pain have access to the treatments they need. 

By understanding the impact of these drugs in the real-world, the FDA is making changes that will make them harder to abuse. With these new guidelines, pharmaceutical manufacturers in the narcotic pain treatment space are prioritizing opioid products with abuse-deterrent properties.

Read More

Topics: Specialty, Market Access

MMIT Reality Check on Viscosupplements (Oct 2017)

Posted by Matt Breese on Oct 20, 2017

According to our recent payer coverage analysis for viscosupplements, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Read More

Topics: Specialty, Market Access, Branding & Marketing

Trends That Matter for Antipsychotic Treatments

Posted by Matt Breese on Oct 12, 2017

Atypical antipsychotics, also known as second-generation antipsychotics, are commonly used to treat conditions such as schizophrenia, bipolar disorder, severe cases of dementiaanxiety disorder and autism.

Clinicians today tend to prescribe atypical antipsychotics instead of typical antipsychotics, which are first-generation treatment options. Industry trends also reveal an increasing range of on-label and off-label uses, according to a report published by the National Center for Biotechnology Information.

Read More

Topics: Specialty, Market Access

Perspectives on Value Frameworks

Posted by Matt Breese on Oct 10, 2017

The pharma industry is experiencing increasing demand from the public and regulatory agencies to define and measure the value of their treatments. Pharma manufacturers today must understand the requirements of many different stakeholders.

The increasing public concern over healthcare costs has led some organizations to define their value frameworks more clearly. Healthcare value frameworks are intended to ensure patients have access to effective, high-quality and responsibly priced treatment options. 

Read More

Topics: Market Access

Formulary Coverage Changes for 2018 Medicare

Posted by Matt Breese on Oct 8, 2017

Over the past couple of years, pharma has seen major shifts in how Medicare sponsors have changed their coverage methodologies. In addition, overall coverage of trending disease areas for Medicare formularies has shifted.

For instance, we've seen major shifts for asthma and COPD treatments within Medicare Part D - with a significant increase in the percentage of lives either not covered or restricted by PAs and step edits.

Read More

Topics: Specialty, Industry Trends, Market Access